vimarsana.com

குறிப்பிட்ட கால இடைவெளியில் பாதுகாப்பு புதுப்பிப்பு அறிக்கைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The 6-Step Checklist For IVDR Compliance

The 6-Step Checklist For IVDR Compliance By Hilde Viroux and Hans Mische, PA Consulting The in vitro diagnostic devices industry has until May 25, 2022 to bring products, documentation, and quality management systems into compliance with the new EU Regulation on In Vitro Diagnostic Devices 746/2017 (IVDR). This regulation is a major revision, focusing on patient safety, requiring more clinical evidence, improving traceability in the supply chain, and enforcing a proactive post-market surveillance system to ensure early detection of problems. The past year presented a challenge in implementing the IVDR while the COVID-19 pandemic forced the industry to focus efforts on bringing COVID-19 tests to the market. The May 2022 deadline is quickly approaching and there is no sign that the EU Commission is considering postponing it. Even if the deadline is pushed back, the expectation is that it would only be for a year, similar to the extension granted for the medical devices regulation. F

Risk-Based Postmarket Surveillance (PMS) In The Age Of EU MDR A Systems Approach

Risk-Based Postmarket Surveillance (PMS) In The Age Of EU MDR: A Systems Approach By Jayet Moon, author of the book As the central focus of the EU’s Medical Device Regulations (MDR), postmarket surveillance (PMS) and its related processes and subsystems have been in the limelight since 2017. This four-part series, using a fresh perspective, takes a bottom-up approach to PMS and starts by elaborating on the state of the art on the incident investigations in Part 1 . “Investigations” are the basic iota of the PMS system upon which all further analysis, synthesis, and decision-making is based. With clarity on this most fundamental unit of PMS, a systems approach to both EU MDR and PMS are explored in

Questions and Answers: Conditional Marketing Authorisation of COVID-19 Vaccines in the EU

Met dank overgenomen van Europese Commissie (EC), gepubliceerd op vrijdag 11 december 2020. With which companies have you concluded COVID-19 vaccine agreements? The Commission is negotiating intensely to build a diversified portfolio of vaccines at fair prices. Contracts have been concluded with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (doses covering 400 million people), BioNTech-Pfizer (300 million doses), CureVac (405 million doses) and Moderna (160 million doses). Member States also have the option to donate vaccines to lower and middle income countries. Which vaccine candidates are currently being reviewed by the European Medicines Agency? The European Medicines Agency (EMA) has received an application for a conditional marketing authorisation for the vaccine developed by BioNTech and Pfizer and will deliver the assessment by 29 December at the latest.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.